Multi-center randomized open label phase II trial on three rituximab dosing schemes in immune thrombocytopenia patients

Haematologica

Volumn 100, Issue 3, 2015, Pages e90-e92

  Zwaginga, Jaap J ^a   van der Holt, Bronno ^b   te Boekhorst, Peter A ^d   Biemond, Bart J ^c   Levin, Mark David ^e   van der Griend, René ^h   Brand, Anneke ^a   Zweegman, Sonja ^g   Pruijt, Hans F M ⁱ   Novotny, Vera M J ^k   Vreugdenhil, Art ^f   de Groot, Marco R ^l   de Weerdt, Okke ^j   van Pampus, Elisabeth C M ^k   van Maanen Lamme, Tanja M ^m   Wittebol, Shulamiet ⁿ   Schipperus, Martin R ^o   Silbermann, Matthijs H ^p   Huijgens, Peter C ^g   Luten, Marleen ^b   Hollestein, Rene ^b   Brakenhoff, Jan A C ^q   Schrama, Jolanda G ^r   Valster, Fransje A A ^s   Velders, Gerjo A ^t   Koene, Harry R ^j   Brand, ^a   Zwaginga, ^a   te Boekhorst, ^d   Koene, ^c,j   Biemond, ^c   Levin, ^u   Vreugdenhil, ^f   Zweegman, ^g   Huijgens, ^g   van der Griend, ^h   Pruijt, ⁱ   de Weerdt, ^j   van Pampus, ^k,v   Novotny, ^k   de Groot, ^l   van Maanen Lamme, ^w   Wittebol, ⁿ   Schipperus, ^o   Silbermann, ^p   Schrama, ^x   Valster, ^s   Velders, ^t   Soesan, ^y   Leeksma, ^z   Tanis, ^aa   Smeets, ^ab   Vasmel, ^z   more..

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ERASMUS MC CANCER INSTITUTE   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d ERASMUS MEDICAL CENTER   (Netherlands)

^e ALBERT SCHWEITZER HOSPITAL   (Netherlands)

^f MÁXIMA MEDICAL CENTER   (Netherlands)

^g VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^h DEPARTMENT OF SURGERY   (Netherlands)

ⁱ JEROEN BOSCH HOSPITAL   (Netherlands)

^j ST ANTONIUS HOSPITAL   (Netherlands)

^k RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^l MEDISCH SPECTRUM TWENTE   (Netherlands)

^m Medisch Spectrum Twente ^*  (Netherlands)

ⁿ MEANDER MEDICAL CENTER   (Netherlands)

^o HAGA HOSPITAL   (Netherlands)

^p TERGOOI HOSPITAL   (Netherlands)

^q Waterland Hospital   (Netherlands)

^r Department of Orthopaedic Surgery   (Netherlands)

^s Lievensberg Hospital   (Netherlands)

^t GELDERSE VALLEI HOSPITAL   (Netherlands)

^u Department of Clinical Chemistry and Haematology   (Netherlands)

^v MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^w Westfriesgasthuis   (Netherlands)

^x Academic Medical Center Amsterdam ^*  (Netherlands)

^y SLOTERVAART HOSPITAL   (Netherlands)

^z ONZE LIEVE VROUWE GASTHUIS   (Netherlands)

^aa GROENE HART HOSPITAL   (Netherlands)

^ab Queen Beatrix Hospital   (Netherlands)

more..

Author keywords

Early response; Immune thrombocytopenia; Open label phase II; Rituximab; Splenectomy delaying

Indexed keywords

CORTICOSTEROID; RITUXIMAB; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY;

ADULT; DRUG DOSE COMPARISON; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; INFECTION; LETTER; MALE; MIDDLE AGED; MULTICENTER STUDY (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENCE FREE SURVIVAL; THROMBOCYTOPENIA; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; ADOLESCENT; AGED; CLINICAL TRIAL; CONTROLLED STUDY; DOSE CALCULATION; DRUG ADMINISTRATION; IMMUNOLOGY; MORTALITY; MULTICENTER STUDY; PATHOLOGY; PHASE 2 CLINICAL TRIAL; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; SURVIVAL ANALYSIS;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; DRUG ADMINISTRATION SCHEDULE; DRUG DOSAGE CALCULATIONS; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; MALE; MIDDLE AGED; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; RECURRENCE; RITUXIMAB; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84946194013     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2014.110213     Document Type: Letter

References (16)

1. Auger S, Duny Y, Rossi JF, et al. Rituximab before splenectomy in adults with primary idiopathic thrombocytopenic purpura: a metaanalysis. Br J Haematol. 2012;158(3):386-398.
2. Patel VL, Mahévas M, Lee SY, et al. Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia. Blood. 2012;119(25):5989-5995.
3. Medeot M, Zaja F, Vianelli N, et al. Rituximab therapy in adult patients with relapsed or refrac- tory immune thrombocytopenic purpura: long- term follow-up results. Eur J Haematol. 2008;81(3): 165-169.
4. Zaja F, Vianelli N, Volpetti S, et al. Low-dose rituximab in adult patients with primary immune thrombocytopenia. Eur J Haematol. 2010;85(4):329-334.
5. Godeau B, Porcher R, Fain O, et al. Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura–results of a prospective multicenter phase 2 study. Blood. 2008;112(4):999-1004.
6. Neunert C, Lim W, Crowther M, et al. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood. 2011;117(16):4190-4207.
7. Ghanima W, Godeau B, Cines DB, et al. How I treat immune thrombocytopenia: the choice between splenectomy or a medical therapy as a second-line treatment. Blood. 2012;120(5):960-969.
8. Godeau B, Stasi R. Is B-cell depletion still a good strategy for treating immune thrombocytopenia? Presse Med. 2014;43(4 Pt 2):e79-85.
9. Arnold DM, Dentali F, Crowther MA, et al. Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann Intern Med. 2007;146(1):25-33.
10. Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2009;113(11):2386-2393.
11. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials. 1989;10(1):1-10.
12. Bussel JB, Lee CS, Seery C, et al. Rituximab and 3 dexamethason cycles provide responses similar to splenectomy in women and those with immune thrombocytopenia less than 2 years duration. Haematologica. 2014;99(7):1264-1271.
13. Li Z, Mou W, Lu G, et al. Low-dose rituximab combined with shortterm glucocorticoids up-regulates Treg cell levels in patients with immune thrombocytopenia. Int J Hematol. 2011;93(1):91-98.
14. Zaja F, Baccarani M, Mazza P, et al. Dexamethasone plus rituximab yields higher sustained response rates than dexamethasone monotherapy in adults with primary immune thrombocytopenia. Blood. 2010;115:2755-2562.
15. Cooper N, Stasi R, Cunningham-Rundles S, et al. The efficacy and safety of B-cell depletion with anti-CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura. Br J Haematol. 2004;125(2):232-239.
16. Stasi R, Del Poeta G, Stipa E, et al. Response to B-cell depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura. Blood. 2007; 110(8):2924-2930.